Panagora Asset Management Inc. reduced its stake in shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 4.0% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 78,027 shares of the biopharmaceutical company’s stock after selling 3,209 shares during the period. Panagora Asset Management Inc.’s holdings in Alexion Pharmaceuticals were worth $10,847,000 at the end of the most recent quarter.
Other hedge funds also recently made changes to their positions in the company. First Hawaiian Bank acquired a new position in Alexion Pharmaceuticals during the 3rd quarter worth $102,000. Advisory Services Network LLC grew its holdings in Alexion Pharmaceuticals by 145.3% during the 2nd quarter. Advisory Services Network LLC now owns 883 shares of the biopharmaceutical company’s stock worth $121,000 after acquiring an additional 523 shares in the last quarter. Columbia Asset Management acquired a new position in Alexion Pharmaceuticals during the 3rd quarter worth $138,000. Checchi Capital Advisers LLC acquired a new position in Alexion Pharmaceuticals during the 3rd quarter worth $204,000. Finally, K.J. Harrison & Partners Inc acquired a new position in Alexion Pharmaceuticals during the 3rd quarter worth $209,000. 93.33% of the stock is owned by institutional investors.
Several research analysts have recently commented on the stock. Oppenheimer set a $165.00 price target on shares of Alexion Pharmaceuticals and gave the company a “buy” rating in a report on Monday, November 26th. Credit Suisse Group set a $156.00 price target on shares of Alexion Pharmaceuticals and gave the company a “buy” rating in a report on Tuesday, November 13th. ValuEngine raised shares of Alexion Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday, November 8th. Zacks Investment Research raised shares of Alexion Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $134.00 price target for the company in a report on Tuesday, October 30th. Finally, Citigroup decreased their price target on shares of Alexion Pharmaceuticals from $195.00 to $190.00 and set a “buy” rating for the company in a report on Thursday, October 25th. Four equities research analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has assigned a strong buy rating to the stock. Alexion Pharmaceuticals presently has a consensus rating of “Buy” and an average target price of $161.50.
Shares of NASDAQ:ALXN opened at $123.15 on Monday. The stock has a market capitalization of $27.47 billion, a P/E ratio of 23.87, a PEG ratio of 1.06 and a beta of 1.01. Alexion Pharmaceuticals, Inc. has a fifty-two week low of $102.10 and a fifty-two week high of $140.77. The company has a debt-to-equity ratio of 0.32, a quick ratio of 2.74 and a current ratio of 3.16.
Alexion Pharmaceuticals (NASDAQ:ALXN) last issued its quarterly earnings data on Wednesday, October 24th. The biopharmaceutical company reported $2.02 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.74 by $0.28. The firm had revenue of $1.03 billion for the quarter, compared to the consensus estimate of $1.02 billion. Alexion Pharmaceuticals had a net margin of 3.90% and a return on equity of 16.60%. Alexion Pharmaceuticals’s quarterly revenue was up 19.5% compared to the same quarter last year. During the same period last year, the firm posted $1.44 EPS. On average, research analysts expect that Alexion Pharmaceuticals, Inc. will post 6.82 earnings per share for the current fiscal year.
About Alexion Pharmaceuticals
Alexion Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers Soliris (eculizumab), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; atypical hemolytic uremic syndrome (aHUS), a genetic disease; and generalized myasthenia gravis, a debilitating, complement-mediated neuromuscular disease.
Recommended Story: How to interpret a stock’s beta number
Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.